Gyre Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 31, 2022 and accepted by EDGAR at Mar 31, 2022, 17:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $7.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $68.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$87.9m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$87.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$83.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | $44.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $51.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $55.7m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $14.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $14.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $41.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-22-012877. Last ingested by Listed: Oct 24, 2026, 15:05 ET. Listed shows no prices and gives no investment advice.